Dosing & Administration

Dosing & Administration

AMVUTTRA® delivers clinical benefits with only 4 doses per year1

Administering AMVUTTRA

  • The recommended dose of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months by a healthcare professional1
  • AMVUTTRA is provided as a fixed dose (25 mg/0.5 mL) prefilled syringe—no dose adjustments required1
  • Injection site reactions may occur1

(See section 2.2 of full Prescribing Information for complete Administration Instructions.)

Missing a dose

  • If a dose is missed, administer AMVUTTRA as soon as possible. Resume dosing every 3 months from the most recently administered dose1

This instructional video for healthcare professionals provides walk-through steps for AMVUTTRA administration.

AMVUTTRA requires the fewest doses to treat ATTR-CM and hATTR-PN1-5*

*No head-to-head trials have been conducted. Conclusions about similarities and/or differences in clinical profiles cannot be drawn.

ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; hATTR-PN=polyneuropathy of hereditary transthyretin-mediated amyloidosis; HCP=healthcare professional.

To learn more about dosing and administration:

Download the Administration Guide 

AMVUTTRA offers confidence in monitoring patient compliance with 
HCP-administered doses only four times per year1

Connect with a Rep

Speak with an Alnylam Representative to learn more about AMVUTTRA.

Connect with a rep

Find a treatment center

Locate a treatment center close to your patients.

View the directory

Up next: Learn more about Access and Support

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References

  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. ONPATTRO Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  3. WAINUA Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP.
  4. VYNDAQEL and VYNDAMAX Prescribing Information. New York, NY: Pfizer, Inc.
  5. ATTRUBY Prescribing Information. Palo Alto, CA: BridgeBio Pharma, Inc.